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From rubella to rotavirus, and beyond
Timo Vesikari*
Vaccine Research Center; University of Tampere; Tampere, Finland
It was customary for medical students
with some ambition to seek their way to a
biomedical research group. I was intrigued
by viruses, and virology was one of the
few subjects in medical school that I stud-
ied with real interest. Next, in late 1966, I
was incredibly lucky to meet Antti Vaheri
(later Professor of Virology) who had just
returned to Finland from the Wistar Insti-
tute in Philadelphia with all the latest
knowledge in rubella research. Rubella
virus hemagglutination had been discov-
ered and with hemagglutination inhibi-
tion (HI) test available I was soon running
a diagnostic rubella laboratory which not
only provided material for research but
also created real income for the Depart-
ment and our group. This set a precedent
for my later professional life. Grants are
good but it is better if the research funding
can be obtained from outside.
We developed the first rubella IgM test
for the diagnosis of recent infection by
separating the 19S (IgM) and 7S (IgG)
antibodies using ultracentrifugation and
testing the fractions using HI test. This
was the mother of all IgM antibody diag-
nostics, and became a Citation Classic by
Current Contents. The rubella IgM test
also opened the door to my later work in
New York, in Dr. Louis Z. Cooper’s (orig-
inally Professor Saul Krugman’s) Rubella
Project in the years 1972–1975. But
before this I made my first contact with
vaccine research.
Live attenuated rubella vaccines were
being developed and the leading candidate
was HPV-77 high passage virus from
NIH. An important open question was
whether the live attenuated vaccine would
cross placenta same way as wild type
rubella virus. The crucial study was to be
done in Finland, away from potentially
damaging publicity in the US, with Dr.
Fred Robbins, a Nobel Laureate, as the
godfather of the project. Under the seniors
I was to do much of work: vaccinate preg-
nant women prescreened to be seronega-
tive for rubella and scheduled to have a
legal abortion a week or two later. The
plan was to isolate rubella (vaccine) virus
from the products of conception and, in
fact, we succeeded in doing that.
Consequently I got an opportunity to
attend an international conference on
rubella vaccination in Bethesda, MD, in
February 1969. This was an eye opener in
many ways. I quickly realized that vaccine
research was as much about science as it
was about politics. The most impressive
spectacle of the conference was Stanley
Plotkin’s presentation on the RA 27/3
candidate rubella vaccine grown in WI-38
human fibroblast cells. By all accounts,
immunogenicity and safety, RA 27/3
appeared superior to HPV77 and its
derivatives, but the number of case histo-
ries of vaccinated subjects fell short of the
required 5000 and the licensure of the
“official candidate” HPV77 was on its
way. The unholy alliance of NIH and
Merck had done everything for the
HPV77/DE5 (five passages in duck
embryo cells at Merck) vaccine to be ready
for licensure in May 1969, with millions
of doses already produced to saturate the
market immediately. As a token sign for
open competition also a Belgian vaccine,
Cendehill strain by Jan Desmyter, was
granted licensure, but had no real chance
in the US market. - As an epilogue,
RA27/3 was later adopted by Merck and
other manufacturers in 1978 to be
included in MMR vaccine.
My time in New York in 1972–1975,
first with New York University of rather Bel-
levue Hospital and then at the Roosevelt
Hospital affiliated with Columbia was highly
interesting, pleasurable and educational, but
not very productive as I was pretty much
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alone running a small laboratory. I learned a
lot about cell-mediated immunity, then a
new and emerging area. I mentored a thesis
work of a visiting scientist, G€uler Kanra, and
made a lifelong friendship with the future
Professor of Pediatrics at Hacettepe Univer-
sity in Ankara, with frequent connections to
Turkey. Another long-lasting friendship was
with my technician TomByrne. I will always
remember his maxim “this is so simple that
even a doctor can do it”. I learned to appreci-
ate many things in the US, first of all that the
eminent position in science was based on
hard work and long hours, which I often
mention to younger colleagues in Finland.
On my return to Finland rubella was
no longer a hot topic. I did my pediatric
residency and reached for new topics. In
the new medical school of the University
of Tampere we learned about the recently
discovered rotavirus and started doing
diagnostic work using electron microscopy
in 1976. The next year together with
Markku M€aki (later Professor of Pediat-
rics) we started a prospective surveillance
on the etiology of acute gastroenteritis in
children and found out that rotavirus was
responsible for 54% of hospital admis-
sions and the rotavirus season was from
December to June. This information was
essential for the first rotavirus vaccine effi-
cacy trial.
I had met Francis Andre in 1977, and
we became good friends until his passing ,
in 2014. Francis was the Scientific and
Medical Director of a Belgian company
RIT, later to become SmithKline-RIT,
SB, and finally GSK. The CEO of the
company was Stan Huygelen, a veterinar-
ian, who had interest in animal diseases
and had acquired a calf rotavirus strain
NCDV for passaging in cell culture
(human rotavirus could not be grown
then) and for eventual development as a
veterinary vaccine. But there was also
cross-reactivity between human and ani-
mal group A rotaviruses. George Zissis
tested the NCDV, now designated as
RIT4237, in gnotobiotic pigs and found
that previous administration of the
“vaccine” protected against challenge by
two human rotaviruses.
The next logical thing to do was to
start human studies. Francis Andre gave
us some doses of RIT4237 to give to
human adult volunteers, including swal-
lowing it myself. There were no symp-
toms, but there was not much of an
immune response either, due to pre-exist-
ing antibodies. We proceeded to children
and observed immune responses but still
no symptoms. Encouraged, we went on to
a quick (not dirty) efficacy trial in 8–11
month-old infants of RIT4237 one dose
vs. placebo with follow-up from January
to May 1983. When analyzing the data
with my younger colleague Erika Isolauri
(later Professor of Pediatrics herself), we
noticed that we had fewer cases in the vac-
cinated group, but the results were clearer
when we looked at the clinical presenta-
tion of the cases so that we introduced the
term “clinically significant diarrhea”, and
against this end point the vaccine had
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conferred 90% protection. - Later, with
Tarja Ruuska, we devised a numerical
score to assess clinical severity more objec-
tively. This has become known as
“Vesikari score”, and many people know
my name from it.
I knew we had something good and
important at hand, a kind of first in the
world. With Francis Andre we designed 17
protocols of which 10 were carried out in
Tampere, Finland, in the next three years, to
cover all areas of rotavirus vaccine, and we
pretty much succeeded in learning more
about rotavirus vaccine and vaccination than
others found in the next 15 years. The idea
was, vis-a-viz the rubella vaccine experience,
to succeed this time and have a European
vaccine licensed and used.
Reviewing what happened helps to
understand how the attitudes have
changed. In Europe, the main obstacle was
lack of data: the significance of rotavirus
disease was not much known or appreci-
ated outside Finland, and few people or
countries were interested in the vaccine. As
it has turned out to be in the 2000’s, every
country will need to do its own epidemiol-
ogy and health economics before consider-
ing a new vaccine, such as rotavirus.
Globally, the reception by the WHO
came as a disappointment. The attitude of
the WHO’s Diarrhoeal Disease Control
(CDD) Programme was generally nega-
tive. It was only later that I realized the
reason was that ours was the wrong vac-
cine. The American dominated CDD was
determined to suppress a European vac-
cine to pave way for US competitors
which were forthcoming but late. The
cited reasons were, among other things
that the vaccine should be 100% effica-
cious against all rotavirus diarrhea and not
only efficacious against severe disease – an
unrealistic requirement that no rotavirus
vaccine has met or will ever meet. The
vaccine should also be efficacious in devel-
oping countries – a reasonable require-
ment, which actually was met if severe
rotavirus diarrhea was the end point. Even
if RIT4237 vaccine was not perfect it was
easy to produce and could have made a
big difference if introduced in the late
1980’s. I still feel sad about thinking how
many lives could have been saved over
twenty years or so if the first oral rotavirus
vaccine had been put in field use with the
same vigor as oral rehydration solution in
those times.
I joined the WHO CDD Programme
for a couple of years (1987–1990). The
experience was mixed. It was great to have
opportunity of traveling the then exotic
countries and work on various studies.
Most of my connections with developing
countries in Asia and also Latin America
are from that time. Within the organiza-
tion, it was disappointing to see how little
academic research or credentials earned in
research were appreciated. When the
CDD Programme was running out steam
and most of funding it was time to leave.
After my return to Finland I became
Professor of Virology and retained my
position as a Head of Pediatric Infectious
Diseases at the Tampere University Hos-
pital. I like to call myself with a line bor-
rowed from Luis Avenda~no (who worked
for a time at NIH), “The best virologist
among pediatricians and the best pediatri-
cian among virologists”.
For a quarter of century I have been a
proponent of rotavirus vaccination in a
generic way, working with all vaccines and
vaccine manufacturers. I had a good work-
ing relationship with Wyeth on Rota-
Shield vaccine, although I always
complained about its high reactogenicity
(intussusception was not yet known).
Together with the vaccine’s developer, Al
Kapikian of NIH, we conducted a study
on neonatal administration of RotaShield
and showed that at this age the vaccine
was safe. Neonatal vaccination was suc-
cessfully applied in a recent study in
Ghana, in an attempt to resurrect the
RotaShield vaccine for use in developing
countries after withdrawal in 1999 for
intussusception. I worked with Al Kapi-
kian on this project until his death in
2014. My advice to Wyeth in the early
1990’s was to launch rhesus-based Rota-
Shield first as a temporary solution but
replace it later with a bovine-human reas-
sortant vaccine (also developed at NIH),
which unfortunately did not happen.
Collaboration with Merck on their
bovine-human reassortant vaccine
RotaTeq, specifically carrying out a major
portion of the REST study, occupied sev-
eral years of almost full-time activity, and
was gratifying as this vaccine was eventually
licensed in 2006. The publication of the
REST study was also a major milestone as it
heralded the new coming of rotavirus vacci-
nation with two new vaccines, RotaTeq
and the human rotavirus vaccine RotarixTM
by GSK. I also worked on the latter since its
first clinical protocol in 2000.
The REST study enabled me to establish
a network of vaccine trial clinics around Fin-
land. The network, collectively part of the
Vaccine Research Center of the University of
Tampere, is now well known among vaccine
manufacturers. In addition to Merck and
GSK, I have worked with Sanofi Pasteur,
SP-MSD, Novartis, Pfizer, Baxter, MedI-
mmune and others (some companies no lon-
ger exist) and the vaccines have included
influenza, varicella, zoster, MMR-V, pneu-
mococcal conjugate, meningococcal vac-
cines, hexavalent combination vaccines, and
many others. Since about 2000, I have been
more or less a professional vaccinologist. In
general, the relationship with industry has
worked well both ways. It is gratifying to be
the Lead Investigator for good vaccines and
see their way to licensure and implementa-
tion with actual impact and benefit to chil-
dren. In addition to rotavirus, such
vaccines include varicella vaccine, intranasal
influenza vaccine and meningococcal group
B vaccine. Reciprocally, many vaccine man-
ufacturers have probably benefited from
close collaboration and communication
with an experienced academic investigator.
At least this is how it was until recently
when large multinational CRO companies
have been outsourced to do much of clini-
cal vaccine research for the manufacturers,
by which the genuine two-way communi-
cation has suffered.
The clinical vaccine trial organization
within the University has over the years
created surplus which I have been able to
use for research. The Vaccine Research
Center has included laboratory compo-
nent for over 20 years. In the 1990’s with
Xiao-Li Pang we discovered that norovi-
ruses were a significant cause of acute gas-
troenteritis in children, actually more
common than rotaviruses if mild cases
were counted. This was the background
for the general idea of vaccinating young
children against noroviruses.
Since the licensure of oral rotavirus
vaccines in 2006 we have been working
on non-live rotavirus vaccine and norovi-
rus vaccines, preferably in combination.
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While I do not do active laboratory work
with my own hands any more, I have a
nice group of investigators supervised by
Vesna Blazevic, a close coworker. The nor-
ovirus components of the vaccine are
based on virus like particles (VLPs). The
rotavirus component is VP6 protein
which, when produced in baculovirus-
insect cell system, self assembles to form
small rod-like structures. VP6 is my old
obsession since the early vaccine trials in
the 1980’s, when Lennart Svensson
showed from our post-vaccination sera
that most of the antibody response was
against VP6, an antigen which was not
appreciated because the antibodies raised
against it were non-neutralizing. It now
appears that VP6 alone may actually
induce protective immunity.
Now that I am retired from my profes-
sorship and no longer engaged in teaching
or hospital work I am actually able to
devote more time to research than before.
I certainly hope to remain active in the
coming years to be able to carry through
clinical trials of our norovirus VLP – rota-
virus VP6 combination vaccine.
My zodiac is Gemini. In my professional
life I have always had two sides, like basic
and clinical research, or virology and pediat-
rics. The balance may have tilted at times,
but I have always been happy to have both
of them, and the feeling is only reinforced
when I talk to my colleagues who are locked
in one subject only. Sometimes the course
of events has not been clear at once. I had
mixed feelings in 1975 on return from New
York to Tampere, to this new Medical
School with insufficient facilities, but then
in a few years realized that luck had been on
my side. I was able to start a significant
career in pediatrics, which in turn opened
entirely new avenues to me. Likewise, the
return in 1990 from Geneva to Finland was
a jump to some uncertainty, but then again
turned out to be a strike of luck as I could
obtain a tailor made position combining
virology and pediatrics, leading to the crea-
tion of Vaccine Research Center and a new
balance between clinical and basic. A com-
fortable position.
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